Tag Archives: LLY

Eli Lilly & Co. (NYSE:LLY) Shares Plunges in Early Session, Boeing’s (NYSE:BA) Hits Deal with Gulf Airline

Posted on May 6, 2013 by Thomas Vedder

silhouette businessman look office window on business buildings As they intend to purchase Boeing’s (NYSE:BA) new 777X jet, Gulf airline tycoons Emirates (EMIRA.UL) and Qatar Airways are cautioning that Boeing must not make the same mistakes of the 787 Dreamliner, which cost users millions of dollars when its …

Posted in Latest Headlines | Tagged BA, Eli Lilly, LLY, NYSE:BA, NYSE:LLY, The Boeing | Comments Off

Healthcare Sector Snapshot: Eli Lilly (NYSE:LLY), Novartis (NYSE:NVS) – LLY, NVS, SNY

Posted on April 25, 2013 by Thomas Vedder

Investors responded negatively to the healthcare stocks on Wednesday. Key movement were observed in Edwards Lifesciences Corp (NYSE:EW) and Amgen, Inc (NASDAQ:AMGN) on percentage decliners side while BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) was prominent stock on percentage gainer side.

Eli Lilly …

Posted in Healthcare, Latest Headlines | Tagged Eli Lilly NYSE:LLY, LLY, Novartis, NVS, NYSE:NVS, NYSE:SNY, Sanofi, SNY | Comments Off

Quick Recap Stock with Major News: Eli Lilly (NYSE:LLY), Barrick Gold (NYSE:ABX) – LLY, ABX

Posted on April 24, 2013 by Thomas Vedder

Eli Lilly & Co (NYSE:LLY) on Wednesday announced higher profit for fiscal Q1, getting benefit from the transfer of some commercial rights. Adjusted quarterly profit surpassed forecasts, while revenues remained unchanged and failed to meet outlook. The corporation reaffirmed its …

Posted in Latest Headlines | Tagged ABX, Barrick Gold, Eli Lilly, LLY, NYSE:ABX, NYSE:LLY | Comments Off

Anthera Pharmaceuticals (NASDAQ:ANTH) Net Loss Narrows in Fiscal Fourth Quarter

Posted on March 27, 2013 by Thomas Vedder

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced on Thursday that net loss in fiscal fourth-quarter was $8.9 million or $0.11 a share, narrower than $29.2 million or $0.71 a share in the similar period a year ago.

Thomson Reuters 7 analysts’ survey …

Posted in Healthcare, Main Post | Tagged ANTH, Anthera Pharmaceuticals, Eli Lilly, IMMU, Immunomedics, LLY, Merck, MRK, NASDAQ:ANTH, NASDAQ:IMMU, NYSE:LLY, NYSE:MRK | Comments Off

Humana Inc.’s (NYSE:HUM) Profit Slips on Inflated Coverage Costs – HUM, LLY, ANTH, RMTI, CTIC, ARNA, LLY,

Posted on February 4, 2013 by Thomas Vedder

Humana Inc.’s (NYSE:HUM) fourth-quarter earnings plunged down 3.5% as inflated coverage costs covered the health-care firm’s revenue growth from hiked membership. Past month, Humana finished its approximately $850 million takeover of Metropolitan Health Networks Inc., a medical-services supplier mainly operating …

Posted in Healthcare, Latest Headlines | Tagged ANTH, Anthera Pharmaceuticals, Arena Pharmaceuticals, ARNA, Cell Therapeutics, CTIC, Eli Lilly, HUM, Humana, LLY, NASDAQ:ANTH, NASDAQ:ARNA, NASDAQ:CTIC, NASDAQ:RMTI, NYSE:HUM, NYSE:LLY, RMTI, Rockwell Medical | Comments Off

Healthcare Sector Recap; Boston Scientific (BSX) Plans to Lower 1000 Jobs while Eli Lilly (LLY) Profit Tumble – BSX, LLY, PFE, KERX, RPRX, SNTA

Posted on January 30, 2013 by Geoff Noir

Last trading session data confirmed that healthcare sector reacted positively with +0.99% change. Keryx Biopharmaceuticals (NASDAQ:KERX) and Repros Therapeutics Inc (NASDAQ:RPRX) were major percentage gainers in this sector while key decliner was Synta Pharmaceuticals Corp (NASDAQ:SNTA).

The Natick, Massachusetts- based …

Posted in Healthcare, Latest Headlines | Tagged Boston Scientific, BSX, Eli Lilly, KERX, Keryx Biopharmaceuticals, LLY, NASDAQ:KERX, NASDAQ:RPRX, NASDAQ:SNTA, NYSE:BSX, NYSE:LLY, NYSE:PFE, PFE, Pfizer, Repros Therapeutics, RPRX, SNTA, Synta | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.